IPO round-up: RainDance seeks $60m from Nasdaq; Weigao,Thyrocare take chance on Asia’s public markets
This article was originally published in Clinica
Executive Summary
Genetic analysis tools developer RainDance Technologies has become the latest medtech firm to file for an initial public offering, targeting up to $60m. The company did not give any pricing details, but it hopes to list on the Nasdaq under the ticker symbol RAIN.